BioCryst Pharmaceuticals

BCRX

Market cap $1.51B

BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.

–   Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – –  ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – –  ORLADEYO oral granules are currently under review with U.S. FDA for ages 2 to

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 12:00 p.m.

BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer William Sheridan - Chief Development Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Stacy Ku - TD Cowen, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Presentation Operator Good day, and welcome to BioCryst Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)—  —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proceeds used to retire all remaining Pharmakon term debt— —Definitive agreement signed to acquire Astria Therapeutics; transaction expected to close Q1 2026— RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determ.